EGFR and neoplasm: Amivantamab is a BsAb targeting EGFR and MET, which can bind to both EGFR and c-MET sites outside of tumor cells and also kill tumor cells through mechanisms such as Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) effect (37).